OneSource Specialty Pharma Ltd
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]
- Market Cap ₹ 20,918 Cr.
- Current Price ₹ 1,825
- High / Low ₹ 2,250 / 1,057
- Stock P/E
- Book Value ₹ 509
- Dividend Yield 0.00 %
- ROCE 0.57 %
- ROE -1.09 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 3.59 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.39% over last 3 years.
- Promoters have pledged 38.4% of their holding.
- Company has high debtors of 177 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 21 | 128 | 39 | 172 | 1,445 | 1,422 | |
| 93 | 132 | 199 | 235 | 978 | 1,117 | |
| Operating Profit | -71 | -4 | -161 | -63 | 467 | 304 |
| OPM % | -334% | -3% | -415% | -37% | 32% | 21% |
| 1 | -128 | -526 | -143 | -94 | 5 | |
| Interest | 16 | 46 | 48 | 89 | 166 | 122 |
| Depreciation | 34 | 53 | 66 | 95 | 274 | 279 |
| Profit before tax | -121 | -231 | -800 | -391 | -68 | -92 |
| Tax % | 0% | -0% | 0% | 0% | -73% | -20% |
| -121 | -231 | -800 | -391 | -18 | -74 | |
| EPS in Rs | -1.57 | -6.44 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 131% |
| 3 Years: | 232% |
| TTM: | -2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 24% |
| TTM: | -161% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -5% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -10% |
| 3 Years: | -2% |
| Last Year: | -1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 3 | 4 | 4 | 11 | 11 |
| Reserves | 774 | 1,009 | 781 | 392 | 5,869 | 5,820 |
| 386 | 1,182 | 864 | 562 | 772 | 1,504 | |
| 96 | 248 | 365 | 468 | 1,005 | 875 | |
| Total Liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,210 |
| 633 | 1,231 | 1,361 | 863 | 6,118 | 6,233 | |
| CWIP | 431 | 490 | 334 | 188 | 218 | 314 |
| Investments | 0 | 0 | 4 | 20 | 16 | 16 |
| 195 | 722 | 314 | 356 | 1,305 | 1,648 | |
| Total Assets | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,210 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| -118 | -416 | -163 | -107 | -68 | 9 | |
| -207 | -692 | -68 | 511 | -201 | -495 | |
| 381 | 1,162 | 118 | -391 | 412 | 359 | |
| Net Cash Flow | 56 | 54 | -112 | 13 | 143 | -127 |
| Free Cash Flow | -325 | -1,071 | -207 | -171 | -196 | -561 |
| CFO/OP | 164% | 10,397% | 108% | 169% | -13% | 6% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 38 | 67 | 36 | 117 | 105 | 177 |
| Inventory Days | 87 | 615 | 258 | 222 | 360 | |
| Days Payable | 762 | 420 | 163 | 147 | 307 | |
| Cash Conversion Cycle | -637 | 67 | 232 | 212 | 180 | 230 |
| Working Capital Days | -2,392 | -1,331 | -6,745 | -877 | -58 | -29 |
| ROCE % | -3% | -12% | -12% | 6% | 1% |
Insights
In beta| Mar 2024 | Mar 2025 | Mar 2026 | Mar 2028 (P) | |
|---|---|---|---|---|
| Cartridge Production Capacity Million Units |
|
|||
| Pre-filled Syringes (PFS) Capacity Million Units |
||||
| Total Workforce (FTEs) Number |
||||
| Vial Production Capacity Million Units |
||||
| Biologics Mammalian Capacity KL |
||||
| Biologics Microbial Capacity KL |
||||
| Customer Advances for DDC Capacity INR Million |
||||
| NCE-1 and NBE Programs Number |
||||
| Biologics Funnel (New projects) Number |
||||
| Developed & Approved ANDAs Number |
||||
| GLP-1 Customers Number |
||||
| Number of Global Customers Number |
||||
| Number of Manufacturing Plants Number |
||||
| Successful Regulatory/Customer Audits Number |
||||
| Technology Transfer Batches Delivered Number |
||||
| Total Successful Audits (Cumulative) Number |
||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
19 May - Intimation of Transcript of Earnings call dated May 13, 2026
-
General- Update
19 May - Prateek Gupta, SVP & Head – Technical Development, resigned effective 15 May 2026.
-
General-Update
16 May - Karnataka approved Unit II expansion under KIP 2025-30; GO received May 15, 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 May - Intimation about publication of newspaper advertisement - Extract of Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
13 May - Audio recording of earnings call for audited FY2026 results made available on May 13, 2026.
Annual reports
Concalls
-
May 2026Transcript PPT
-
Jan 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Sep 2025TranscriptAI SummaryPPT
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.